We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris – Part 1: treatment and monitoring recommendations.
- Authors
Nast, A.; Smith, C.; Spuls, P.I.; Avila Valle, G.; Bata‐Csörgö, Z.; Boonen, H.; De Jong, E.; Garcia‐Doval, I.; Gisondi, P.; Kaur‐Knudsen, D.; Mahil, S.; Mälkönen, T.; Maul, J.T.; Mburu, S.; Mrowietz, U.; Reich, K.; Remenyik, E.; Rønholt, K.M.; Sator, P.G.; Schmitt‐Egenolf, M.
- Abstract
This evidence‐ and consensus‐based guideline on the treatment of psoriasis vulgaris was developed following the EuroGuiDerm Guideline and Consensus Statement Development Manual. The first part of the guideline includes general information on the scope and purpose, health questions covered, target users and strength/limitations of the guideline. Suggestions for disease severity grading and treatment goals are provided. It presents the general treatment recommendations as well as detailed management and monitoring recommendations for the individual drugs. The treatment options discussed in this guideline are as follows: acitretin, ciclosporin, fumarates, methotrexate, adalimumab, apremilast, brodalumab, certolizumab pegol, etanercept, guselkumab, infliximab, ixekizumab, risankizumab, secukinumab, tildrakizumab and ustekinumab.
- Subjects
PSORIASIS; GUIDELINES; THERAPEUTICS; METHOTREXATE; ETANERCEPT
- Publication
Journal of the European Academy of Dermatology & Venereology, 2020, Vol 34, Issue 11, p2461
- ISSN
0926-9959
- Publication type
Article
- DOI
10.1111/jdv.16915